Voices
Shaheenah Dawood: FDA Fast Tracks First-in-Class TNFR2 Antibody in Ovarian Cancer
Shaheenah Dawood/LinkedIn

Shaheenah Dawood: FDA Fast Tracks First-in-Class TNFR2 Antibody in Ovarian Cancer

Shaheenah Dawood, Consultant Medical Oncologist, Professor in Clinical Oncology, and Head of the Oncology Clinical Trials Program at Mediclinic City Hospital in Dubai, shared on LinkedIn:

“FDA has granted fast track designation to BioInvent International’s BI-1808, a first-in-class anti-TNFR2 antibody, for the treatment of ovarian cancer in combination with pembrolizumab.

The designation is based on interim phase 2a data presented at the ASCO 2026.”

Shaheenah Dawood: FDA Fast Tracks First-in-Class TNFR2 Antibody in Ovarian Cancer

Other articles about FDA  on OncoDaily.

Antibody Therapy ASCO 2026 BI-1808 cancer cancer immunotherapy clinical trials drug development FDA FDA Fast Track Gynecologic Oncology immunotherapy OncoDaily Oncology Ovarian Cancer pembrolizumab Phase 2 Precision Oncology Shaheenah Dawood TNFR2 TNFR2 antibody